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and Liver X Receptor Activation in the PANDER Transgenic
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Abstract
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PANcreatic-DERived factor (PANDER) is a member of a superfamily of FAM3 proteins
modulating glycemic levels by metabolic regulation of the liver and pancreas. The precise
PANDER-induced hepatic signaling mechanism is still being elucidated and has been very
complex due to the pleiotropic nature of this novel hormone. Our PANDER transgenic (PANTG)
mouse displays a selective hepatic insulin resistant (SHIR) phenotype whereby insulin signaling is
blunted yet lipogenesis is increased, a phenomena observed in type 2 diabetes. To examine the
complex PANDER-induced mechanism of SHIR, we utilized quantitative mass spectrometry based
proteomic analysis using Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) to
reveal the global hepatic proteome differences within the PANTG under the metabolic states of
fasting, fed and insulin-stimulated conditions. Proteomic analysis identified lipid metabolism as
one of the top cellular functions differentially altered in all metabolic states. Differentially
expressed proteins within the PANTG having a lipid metabolic role included ACC, ACLY, CD36,
CYP7A1, FASN and SCD1. Central to the differentially expressed proteins involved in lipid
metabolism was the predicted activation of the liver X receptor (LXR) pathway. Western analysis
validated the increased hepatic expression of LXRα along with LXR-directed targets such as
FASN and CYP7A1 within the PANTG liver. Furthermore, recombinant PANDER was capable of
inducing LXR promoter activity in-vitro as determined by luciferase reporter assays. Taken
together, PANDER strongly impacts hepatic lipid metabolism across metabolic states and may
induce a SHIR phenotype via the LXR pathway

Author Manuscript

Keywords
Fam3B; PANDER; liver; lipogenesis; fatty acid synthesis; Liver X Receptor; SILAC; proteomics

*

Corresponding Author: Brant R. Burkhardt, Ph.D., Department of Cell Biology, Microbiology and Molecular Biology, University of
South Florida, 4202 East Fowler Avenue, BSF 206, Tampa, FL 33620, Tel: 813-974-5968, Fax: 813-974-1644, bburkhardt@usf.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Athanason et al.

Page 2

Author Manuscript

1. INTRODUCTION
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Over the past decade PANcreatic-DERived factor (PANDER or FAM3B) has been
investigated with regard to secretion from the endocrine pancreas and biological impact on
glycemic regulation both in-vitro and in-vivo (Zhu, Xu, Patel et al., 2002, Burkhardt, Cook,
Young et al., 2008, Burkhardt, Greene, White et al., 2006, Cao, Yang, Burkhardt et al., 2005,
Hou, Wang, Li et al., 2011, Mou, Li, Yao et al., 2013, Robert, 2005, Robert-Cooperman,
Carnegie, Wilson et al., 2010, Wang, Cai, Pang et al., 2008, Xiang, Chen and Yang, 2012,
Xu, Gao, Wu et al., 2005, Yang, Gao, Robert et al., 2005, Yang, Robert, Burkhardt et al.,
2005, Zhuang, Guan, Gao et al., 2011). Our recently generated pancreas specific
overexpressing transgenic mouse model (PANTG) exhibits both fasting and fed glucose
intolerance primarily attributed to impaired hepatic insulin signaling concordantly coupled
with both increased gluconeogenesis and lipogenesis (Robert-Cooperman, Dougan, Moak et
al., 2014). This result is consistent with other PANDER animal models that acutely express
PANDER within the liver via adenoviral delivery (Li, Chi, Wang et al., 2011). The
mechanism by which PANDER inhibits hepatic insulin signaling has been attributed to
suppressed phosphorylation of Akt (Yang, Wang, Li et al., 2009) and AMPK (RobertCooperman et al., 2014). Both of which serve as major regulators of gluconeogenesis.
However, a major paradox to PANDER signaling has been the documented increase in
hepatic lipogenesis despite inhibited insulin signaling (Robert-Cooperman et al., 2014, Li et
al., 2011). This bifurcation of signaling results in a selective insulin resistant state that
mimics what is observed in T2D animal models and humans (Biddinger, Hernandez-Ono,
Rask-Madsen et al., 2008, Brown and Goldstein, 2008). Encompassing prior PANDER
research, an emerging hypothesis suggests that the pathophysiological conditions of T2D
could potentially induce increased circulating PANDER levels contributing to selective
hepatic insulin resistance (SHIR) resulting in increased hepatic glucose output and
lipogenesis (Wilson, Robert-Cooperman and Burkhardt, 2011, Wang, Burkhardt, Guan et al.,
2012), as precisely observed in our PANTG model. Recent evidence has now indicated that
circulating PANDER levels are elevated and associated with metabolic syndrome
components in a Chinese population (Cao, Yang, Lai et al., 2015). Plasma PANDER levels
significantly correlated with fasting plasma glucose, 2 hour plasma glucose, and triglyceride
levels. Between animal model results and recent clinical studies, an emerging theme with
PANDER is the possible role of this novel hormone in the promotion of hepatic insulin
resistance and lipogenesis. Despite this importance, the precise PANDER-induced signaling
mechanism in the liver has yet to be determined.
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To elucidate PANDER-induced hepatic molecular mechanisms, we utilized quantitative
mass spectrometry-based proteomic analysis via a stable isotope labeling by amino acids in
cell culture (SILAC) approach to characterize hepatic proteomic differences between the
PANTG murine liver with that of wild-type mice under three metabolic states: fasting, fed,
and insulin-stimulated. To achieve this, stable isotope-labeled liver protein lysate from mice
that were metabolically labeled with 13C6-Lys was utilized as an internal standard for
relative quantification of global proteome differences in the liver, a technique rarely used to
study metabolic disorders yet previously validated from examination of insulin signaling and
liver proteomic characterization. Differentially expressed proteins using this approach can be
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analyzed with bioinformatics tools such as Ingenuity Pathway Analysis (IPA) in order to
reveal altered molecular networks and their function as well as differences in canonical
pathways that can be later validated via additional molecular approaches. This unbiased,
global-scale approach has led to novel insight into PANDER-induced hepatic pathway
alterations in our PANTG model, in particular, those related to increased lipogenesis.

2. MATERIALS AND METHODS
2.1. Transgenic mouse generation and genotyping
Generation and original phenotyping of the PANDER transgenic mouse was described
previously (Robert-Cooperman et al., 2014). In brief, this murine model overexpresses
PANDER from the endocrine pancreas resulting in increased levels of circulating PANDER
with a phenotype of impaired glucose tolerance and hepatic insulin sensitivity.
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2.2. Proteomic Experimental Design
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The purpose of this study was to examine the PANDER-induced hepatic proteome in various
metabolic states. As outlined in Fig. 1, the PANTG mouse was exposed to fasted, fed, and
insulin stimulatory conditions prior to liver extraction and subsequent proteomic
examination. All treatments were performed on PANTG and wild-type mice at six weeks of
age. Fed and fasted mice were withheld from food for approximately 4 and 16 hours,
respectively. Following the 4 hour fast, fed mice were provided with chow ad-libitum for 2
hours. Insulin-stimulated mice were fasted for 4 hours prior to insulin injection (Humulin®,
1 unit/kg). Insulin was diluted to 20 units/ml and injected intraperitoneally with exposure for
15 minutes. Mice were humanely euthanized by carbon dioxide asphyxiation and cervical
dislocation following above described metabolic conditions. Livers were extracted
immediately following exposure to described metabolic conditions, snap frozen and stored at
−80°C prior to proteomic analysis.
2.3. Hepatic Protein Isolation
Approximately 40 mg of tissue was excised from a lobe of mouse liver for tissue lysis.
Tissue was submerged in cold lysis buffer (100mM Tris-HCl, 100mM DTT, 4% SDS and 1x
HALT protease inhibitor) and homogenized using a Qiagen TissueRupter. Cell lysate was
then heated at 95°C for five minutes followed by brief sonication. The tissue lysate was
cleared by centrifugation at 16000× g for 5 min and the supernatant was collected and stored
at −80°C prior to further analysis. The same procedure for protein purification was
performed on the “heavy” labeled (13C6 L-Lysine) murine male liver (MT-LYSC6-ML-PK,
Cambridge Isotope Laboratories, Inc.).
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2.4. Sample digestion, desalt and SCX fractionation
Protein concentration was quantified using the Pierce 660 nm protein assay kit supplemented
with the provided ionic detergent compatibility reagent (IDCR). Equal mass of labeled and
unlabeled protein or “light” and “heavy” protein respectively, were combined and digested
using the filter-aided sample preparation (FASP) method (Expedeon). Briefly, 30 μL of the
protein mixture (~12.5mg/ml) was added to the spin column. The lysate buffer was
exchanged to 8M urea using centrifugation prior to alkylation by iodoacetamide. The
Mol Cell Endocrinol. Author manuscript; available in PMC 2018 January 30.
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solution was then exchanged to 50 mM ammonium bicarbonate for trypsin/Lys-C digestion
at a ratio of 1:40 (w/w). Digestion was carried out overnight in a humidified incubator at
37°C. Peptides were eluted off the column by addition of 0.5M NaCl followed by
centrifugation.
Samples were desalted using solid phase enrichment C18 columns (The Nest Group, Inc.).
Briefly, columns were activated using 100% acetonitrile followed by equilibration with 0.1%
formic acid in water. Samples were loaded onto the columns and washed three times using
equal volumes of 0.1% formic acid in water. Samples were eluted using 90% acetonitrile/
0.1% formic acid in water and then concentrated in a vacuum concentrator (Thermo) prior to
resuspension with 5 mM ammonium formate and 25% acetonitrile. Peptides were
fractionated by strong cation exchange chromatography as previously described (BellTemin, Culver-Cochran, Chaput et al., 2015).
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2.5. LC-MS/MS and pathway analysis
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Fractions were separated on a 10 cm × 75 μm I.D. reversed phase column packed with 5 μm
C18 material with 300 Å pore size (New Objective) using 120 minute gradients of 2–40%
ACN in 0.1% formic acid. Inline mass spectrometric analysis was performed on a hydrid
linear ion trap-Orbitrap mass spectrometer (Orbitrap XL (Thermo Fisher Scientific). Full
MS survey scans were performed at a resolving power of 60000, and the top 10 most
abundant peaks were selected for subsequent MS/MS analysis in the linear ion trap. Raw
files were processed in MaxQuant 1.2.2.5 employing the Andromeda search algorithm and
searched against the UniprotKB reference database for Mus musculus, concatenated with
reversed protein sequences. A second database of known contaminants provided with the
MaxQuant suite was also employed. All fractions for each biological sample were combined
for analysis. Constant modification of carbamidomethylation of cysteine and variable
modifications of oxidized methionine and acetylated protein N-termini were used.
Additionally, Lys-6 for the spike-in internal standard was set as a label in the group-specific
parameter section. A false discovery rate of 1% was used for peptides and proteins. A
minimum peptide length of 6 amino acids was used. Razor and unique peptides were used
for identification and quantification. Protein ratio values were reconstructed using median
peptide ratio values across all three biological replicates for each experimental group where
the final ratio for each protein was calculated by determining the ratio-of-ratio (PANTG/
Internal Standard/(WT/Internal Standard). Final ratios were input into the Perseus
processing suite (Perseus version 1.2.0.13). Statistical analysis was performed using the
Significance A outlier test where statistical significance based on magnitude fold-change
was established at P < 0.05. Ratio values and Uniprot Protein identification numbers of
differentially expressed proteins were uploaded to Ingenuity Pathway Analysis (IPA) to
determine canonical pathways, networks and upstream regulators in the liver affected by
increased pancreas-secreted PANDER. We note that the outlier test based on the ratio
distribution of the combined replicates was performed to increase coverage depth of
differentially expressed proteins. The limitation of this approach is the increased false
discovery rate of differentially expressed proteins as variance within groups is not
specifically considered in the statistical filtering. Given only lysine-terminated tryptic
peptides were used for relative quantitation, coverage of quantifiable proteins was limited
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(more so for lower abundance proteins) and therefore the Significance A filtering approach
was utilized in order to enhance bioinformatic analysis. Additionally, we have generated a
modified ProteinGroups file generated by MaxQuant that lists relative expression ratios for
each biological replicate, showing all proteins with measurable relative standard deviation
(RSD) values. In order to achieve statistical significance based on 1.5-fold change in
expression (relative to wild-type, which is a value close to the Significance A test cut-off for
significance at p<0.05 for the three metabolic conditions) using the Student’s t-test (with the
assumption that variance is the same at higher expression), approximately 30% RSD or less
would be needed. For higher fold-change values (>2-fold), statistical significance using the
Student’s t-test could be achieved at RSD values measured for most proteins in the modified
ProteinGroups file. The modified protein list represents all hepatic proteins that are
quantifiable with the methodology and instrumentation used in this study. This file as well as
all mass spectrometric data have been deposited to the ProteomeXchange Consortium via
the PRIDE partner repository with the dataset identifier PXD004171 and 10.6019/
PXD004171. In addition, further raw data and a detailed description of the proteomic
analysis can be found in the Data in Brief manuscript associated with this study including
Venn-Diagrams of unique proteins across metabolic states (Fig. 1, Data in Brief article) and
complete listing of all differentially expressed proteins (Supplementary Tables 1–3, Data in
Brief article) (Athanason, 2016).
2.6. Immunoblotting
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Approximately 100 mg of tissue was excised from a lobe of mouse liver for tissue lysis.
Liver samples were identical from those obtained during the SILAC analysis as detailed
earlier. In brief, following isolation the liver was submerged in cold T-PER lysis buffer
(Thermo) supplemented with 1X HALT protease inhibitor and lysed using a Qiagen
TissueRupter until tissue debris was no longer visible. Cellular lysate was then heated at
95°C for five minutes followed by brief sonication. The tissue lysate was cleared by
centrifugation at 16000× g for 5 min and the supernatant was collected and stored at −80°C
prior to further analysis. Protein concentration was quantified using the Pierce BCA Protein
assay following the manufacturer’s protocol. Fifty μg was separated by SDS-PAGE (MiniPROTEAN TGX Pre-Cast gels, 4–20%) and electro-transferred to a PVDF membrane using
the iBlot semi-dry transfer apparatus (Invitrogen). PVDF membranes were then probed with
primary antibodies against FAS, (C20G5, Cell Signaling Technology), LXRα (P-20, Santa
Cruz), and CYP7A1 (ab65596, Abcam). All primary antibodies were diluted 1:500 in
StartBlock Blocking Buffer (Thermo). Detection was achieved utilizing horseradishperoxidase-conjugated goat secondary antibody (Bio-Rad) diluted 1:10,000 in StartBlock
followed by chemiluminescence detection using Pierce ECL Western Blotting Substrate
(Thermo). Emitted signal was detected using the Amersham™ Imager 600 (GE Healthcare
Life Sciences). Relative protein levels were normalized to GAPDH (2118, Cell Signaling)
and expression levels and densitometry analysis were quantified with ImageQuantTL (GE
Healthcare Life Sciences).
2.7. Cell culture and transient transfections
BNL-CL2 (BALB/c embryonic normal liver) cells were cultured until passage five in
standard DMEM (4.5g/L glucose, L-glutamine and sodium pyruvate) supplemented with
Mol Cell Endocrinol. Author manuscript; available in PMC 2018 January 30.
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10% FBS and 1% PenStrep (Thermo) at 37 °C, 5% CO2. Approximately 2 × 105 cells per
well were plated in a tissue culture treated 24-well dish (Becton-Dickinson). After 24 hours,
media was replaced with DMEM without glucose, L-glutamine and sodium pyruvate
supplemented with 1% FBS for 4 hours prior to transfection. LXRα signaling plasmids and
control plasmids (Cignal Reporter Assay Kit, Qiagen) were transfected using Lipofectamine
2000 (Invitrogen, Carlsbad, CA). Transfection of each plasmid was performed in triplicate in
two independent experiments. Two hours post transfection, media was replaced with DMEM
supplemented with 1% FBS and 1% PenStrep with the addition of PANDER (0.25 nM, 0.5
nM and 1nM) for 18 hours. Cells were washed with PBS and lysed in 100 μl of 1X Glo
Lysis Buffer (Promega), utilizing the Dual-Luciferase Reporter Assay System (Promega) for
luciferase activation. Signal emission was detected with a Monolight 3010 luminometer
(Analytical Luminescence Laboratory, San Diego, CA).
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3. RESULTS
3.1 SILAC Proteomic characterization of PANTG liver reveals increased hepatic lipogenesis
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To comprehensively examine the PANDER-induced hepatic proteome, we performed
SILAC-based quantitative proteomics on our PANTG model. The PANTG is an ideal
candidate for our investigation due to pancreatic-specific overexpression of PANDER
resulting in robust increased circulating levels as compared to wild-type mice along with
resultant impaired glucose tolerance, hepatic insulin resistance and increased hepatic
triglyceride levels (Robert-Cooperman et al., 2014). Our quantitative proteomic approach
was performed on the PANTG model in comparison to WT mice in the context of 3
metabolic conditions of fasting, fed and insulin-stimulated to examine the impact of
PANDER across numerous metabolic states. Following exposure to the various metabolic
conditions, livers from PANTG and age/gender matched WT mice were collected and
subsequently processed by tryptic digestion, desalting and SCX chromatography followed
by mass spectrometry as detailed in Figure 1. Across all metabolic conditions, MaxQuant
identified a total of 19,423 unique peptides (Complete data files deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier
PXD004171 and 10.6019/PXD004171). Of those, there were 228, 239 and 189 significantly
differently expressed and quantifiable proteins in the fasted, fed and insulin-stimulated
conditions within the PANTG liver as compared to WT, respectively (Listed in
Supplementary Table 1 and fully detailed in reference (Athanason, 2016). Based on
proteomic examination by IPA of the differentially expressed proteins, the top predicted
primary molecular and cellular functions altered in the PANTG for all metabolic states was
lipid metabolism based on −log(p-value) score as determined using the Significance A
outlier test (Fig. 2). Within the fasting, fed and insulin-stimulated conditions, 51, 42 and 50
differentially expressed proteins, respectively, with lipogenic associated functions were
identified (Listed in Supplementary Table 2 and fully detailed in reference (Athanason,
2016). The most significant metabolic changes in the predicted activation state were found
during insulin stimulation with numerous functions having a significant predicted activation
as determined by z-score in IPA (z-score values >2 or <−2 indicate activation or inhibition,
respectively). These functions included fatty acid synthesis, concentration of lipid,
concentration of fatty acid, oxidation of lipid and conversion of lipid (Table 1). The most
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significantly activated lipogenic that were identified included fatty acid synthesis and
concentration of lipid with 27 proteins converging on these predicted activated networks
(Figure 3).
Some of the most notable differentially expressed enzymes involved in lipogenesis included
fatty acid synthase (FASN), ATP citrate lyase (ACLY), and sterol-CoA desaturase-1 (SCD)
(Fig 3.).
3.2. Proteomic identification of PANDER-induced hepatic LXR pathway
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Due to the significant change in hepatic lipogenesis as determined by our proteomic
approach, a mechanism or canonical pathway was then evaluated to potentially identify the
etiology supporting this phenotype. Therefore, IPA was used to identify putative canonical
pathways in all metabolic states that could potentially regulate the observed lipogenic
pathways. Network analysis revealed that Liver X Receptor activation was identified as the
most significantly predicted overall affected pathway across metabolic states (Fig. 4). In
addition, acute phase response signaling was also revealed as a significant canonical
pathway.
3.3. Validation of PANDER-induced hepatic LXR pathway and fatty acid synthase
expression
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Liver X receptors (LXR) are transcription factors belonging to the class II nuclear receptor
superfamily and are composed of 2 isoforms (Edwards, Kennedy and Mak, 2002, Steffensen
and Gustafsson, 2004, Ducheix, Montagner, Theodorou et al., 2013). LXRα is highly
expressed in the liver, intestine, and adipose tissues whereas LXRβ is ubiquitously
expressed. Upon activation, LXRs form a heterodimer with the retinoid X receptor α, which
binds to LXR response elements and enhances targeted gene expression in a functionaldependent manner. LXRs appear to regulate overall glucose, cholesterol, bile acid, and
triglyceride homeostasis (Baranowski, 2008). One of the most critical gene targets governed
by LXR involved in lipogenesis is FASN, which was shown by our proteomic analysis to be
significantly increased in PANTG livers in all metabolic states (Joseph, Laffitte, Patel et al.,
2002, Talukdar and Hillgartner, 2006) (Supplementary Table 2). Several LXR targets
including FASN and SCD1 not only pass the Significance A outlier test based on the ratio
distribution of the combined biological replicates but also demonstrate statistical
significance using the t-test (p<0.05) in the insulin-stimulated group. Other targets such as
CYP7A1 and CD36 are lower abundance proteins with limited peptide coverage, which
affect quantitation accuracy. Therefore, these proteins require further validation by a targeted
approach such as western blot analysis. We then sought to precisely examine expression of
LXR and dominant targets of LXR such as FASN and CYP7A1 in the PANTG liver. Livers
obtained during the proteomic investigation of PANTG were also examined for levels of
LXRα expression. In brief, PANTG and WT livers obtained and snap-frozen as previously
detailed for the proteomic analysis were probed for LXRα, FASN and CYP7A1 expression
by western analysis. Samples from the insulin-stimulated conditions were examined since
this metabolic condition demonstrated the most significant differentially expressed lipid
metabolism network (Fig. 2). During insulin-stimulated conditions, LXRα was significantly
increased (Image J, P<0.05) as compared to WT liver expression (Fig. 5). Levels of LXRβ
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were similar between PANTG and WT (data not shown). In addition, hepatic expression of
FASN and CYP7A1 were increased during insulin-stimulated conditions (Image J, P<0.05).
In summary, LXRα and critical LXRα targets such as FASN and CYP7A1 were increased
in PANTG model and indicates this pathway may potentially be activated during conditions
of high circulating PANDER.
3.4. PANDER stimulates LXR transcriptional activity in-vitro
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The above studies examined the abundance of LXR and targets of LXR in the PANTG liver.
However, we will also wanted to determine if PANDER may govern or induce LXR
transcriptional activity. To examine this, reporter gene analysis was performed using a
commercially available LXR response element (LXRE) mediated luciferase assay (Qiagen,
Cignal LXR Reporter Kit). This LXRα reporter assay measures the transcriptional activity
of liver X receptor (LXR) and this was determined in the context of exogenous PANDER
application. A liver derived cell line, BNL-CL2, was exposed to increasing concentrations of
purified secreted PANDER (AstraZeneca) and LXR-directed transcriptional activity was
measured. PANDER can significantly increase LXRE directed luciferase expression at a
range of concentrations from 0.25 to 1 nM in a dose-dependent manner (Figure 6).
Therefore, as matched with increased LXR expression in the liver of the PANTG, PANDER
is also capable of directly stimulating LXR-directed transcriptional activity in-vitro.

4. DISCUSSION
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This proteomic examination of the PANTG provided important mechanistic insight
pertaining to the putative mechanism impacting lipid metabolism in the liver of mice with
increased circulating PANDER sourced from the endocrine pancreas. Additionally, we
demonstrated the strong utility for the implementation of quantitative mass spectrometry
based proteomics for the investigation of metabolic disorders or the characterization of novel
hormones regulating intracellular signaling. Evidence to date has demonstrated that
PANDER can promote a selective hepatic insulin resistant (SHIR) phenotype whereby
insulin signaling is partially inhibited and therefore hepatic glucose production and
lipogenesis is increased (Robert-Cooperman et al., 2014), phenomena observed in T2D
animal models and clinical human observations (Brown and Goldstein, 2008). Earlier studies
demonstrated that PANDER overexpression induces fasting hyperglycemia by upregulating
gluconeogenic gene pathways and subsequently increasing hepatic glucose output in mice
(Robert-Cooperman et al., 2014, Li et al., 2011, Wilson, Schupp, Burkhardt et al., 2010).
These effects were attributed to the presence of increased transcript levels of PEPCK and
Glucose 6-phosphatase (G6Pase) due to inhibited phosphorylation of critical insulin
signaling molecules such as Akt and AMPK. However, these similar studies revealed
increased hepatic lipogenesis despite suppressed insulin signaling. Therefore, due to the
complex nature of this metabolic process, we employed a comprehensive proteomic
approach to identify putative novel mechanisms of this process. Our MS based methods
demonstrated a proteomic profile similar to the observed lipogenic phenotype and supports
the utility of using this tool to unravel complex signaling mechanisms.
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With the creation of our pancreas-specific overexpressing mouse model, we have recently
reported that the PANTG mice display fasting hyperglycemia attributed to impaired hepatic
insulin sensitivity when circulating PANDER is overexpressed. A similar proteomic
approach in the PANTG revealed upregulation of PEPCK and indicated a mechanism of
PANDER-induced gluconeogenesis (Robert-Cooperman et al., 2014). This approach was
limited though since our previous SILAC analysis employed ethanol treated AML-12 cells
(murine hepatic cell line) to serve as the control “spike-in” internal standard for the liver and
utilized for protein comparison. In addition, the prior proteomic examination was performed
during a random re-fed uncontrolled metabolic state. This experimental design was certainly
not ideal for making important comparisons during metabolic states and examining changes
in the hepatic proteome. Therefore, our current approach employed controlled metabolic
states (fasting, controlled fed, and insulin-stimulated) with a SILAC-labeled C57BL/6J
murine liver (not AML-12 cell line) and evaluated in the established PANTG model. In our
current study, we utilized a metabolically labeled “SILAC” mouse liver to provide a superior
internal standard enhancing the capability to capture differences in the PANTG liver
proteome as compared to the WT control.
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Our proteomic data strongly complements the described published studies on PANDER’s
role in the mouse liver with regard to inducing increased hepatic lipogenesis which has long
been attributed to hyperinsulinemia (Assimacopoulos-Jeannet, Brichard, Rencurel et al.,
1995), a hallmark of T2D and non-alcoholic fatty liver disease (Wanless and Lentz, 1990,
Group, 1979). However, pertaining to lipid metabolism in the PANTG liver, little is known
of the biochemistry generating the increase of lipid production, especially fatty acid
synthesis and lipogenesis. In our study we have provided data indicating that PANDER
overexpression acts to increase gene expression modulated by a similar nuclear binding
protein: the liver X receptor (LXR). Insulin mediated activation of lipogenic pathways has
been described extensively. LXR has been shown to drive overexpression of lipogenic genes
in hyperinsulinemia conditions (Yoshikawa, Shimano, Amemiya-Kudo et al., 2001, Chen,
Liang, Ou et al., 2004). Since the most significant effects of PANDER were observed during
insulin-stimulatory conditions, our data suggests that PANDER acts in concert with insulin
to potentially promote hepatic lipid production and fatty acid synthesis. Given the fact that
PANDER does appear to be located within pancreatic β-cell insulin granules (Xu et al.,
2005, Cao, Gao, Robert et al., 2003), this co-packaging may indicate complementary
functionality in terms of distal biological effects on target tissues such as the liver. Increased
hepatic lipid metabolism was also observed by proteomic analysis during fasting and fed
conditions but not to the same level of statistical significance as insulin-stimulated. There are
several potential putative mechanisms describing this effect. As mentioned previously,
increased lipogenic gene regulation by PPARγ regulation has been described by blunted
FOXO1 signaling (Li et al., 2011). Interestingly, our network analysis also indicated that
PPARγ was a significantly predicted upstream regulator of the observed lipogenic effect in
our PANTG model (data not shown). Alternatively, recent studies have indicated that
Carbohydrate-Responsive Element Binding Protein (ChREBP) binds directly to the
PANDER promoter (Ratliff, Athanason, Chechele et al., 2015). This gene plays a key role in
the control of lipogenesis through the regulation of lipogenic genes (Dentin, Benhamed,
Hainault et al., 2006, Iizuka, 2013). PANDER may be acting in concert with ChREBP
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enhancing PANDER-induced lipogenesis (Ratliff et al., 2015). Our current data suggests a
novel putative mechanism that implicates LXR as a key modulator of genes driving a hepatic
steatotic phenotype in the PANTG mice. In the insulin-stimulated condition we saw this
effect exaggerated where downstream targets of LXR such as FASN, ACC, SCD1, CYP7A1
and CD36 are all upregulated. Additionally, LDL was increased in the PANTG liver
suggesting an increase of intercellular oxysterols. Oxysterol is the main activating ligand
required for LXR-RXR dimerization (Janowski, Willy, Devi et al., 1996). LDL influx is
mediated by certain cell membrane transporters, CD36 being one of them (Calvo, GómezCoronado, Suárez et al., 1998), leading to an increase in intracellular cholesterol content that
can be subsequently oxidized (Noguchi, Numano, Kaneda et al., 1998). Taken together, we
have demonstrated and validated that the LXR signaling pathway may be involved in
PANDER-induced hepatic lipogenesis.
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As detailed in prior review articles, PANDER has widespread interactions with both the liver
and the endocrine pancreas (Wilson et al., 2011, Wang et al., 2012, Yang and Guan, 2013).
Pancreatic islets obtained from the PANDER knockout mouse (PANDER KO) displayed an
impaired glucose stimulated insulin secretion (GSIS) (Robert-Cooperman et al., 2010). The
mechanism for this decreased biological function has yet to be determined precisely,
although the observed inhibited intracellular Ca2+ response is believed to have a role in the
impaired GSIS of the PANKO model. Importantly, LXR activation has been demonstrated to
stimulate insulin secretion upon T0901317 (agonist of LXR) activation and promoting
expression of FASN and ACC (also increased in our PANTG) in pancreatic islets (Efanov,
Sewing, Bokvist et al., 2004, Efanov, Sewing, Bokvist et al., 2004). Concordantly, pancreatic
islets from LXR knockout mice have disrupted GSIS with increased lipid deposition (Gerin,
Dolinsky, Shackman et al., 2005). Although not experimentally confirmed in the PANKO
model, the absence of PANDER may have inhibited pancreatic LXR expression resulting in
the observed impaired GSIS. Another highly relevant finding is that chronic LXR activation
particularly under high glucose conditions promotes pancreatic β-cells apoptosis (Choe,
Choi, Kim et al., 2007). An identical biological effect that was initially widely reported for
PANDER (Cao et al., 2003). Some of the earliest investigations demonstrated that PANDER
could induced apoptosis of pancreatic β-cells and cell lines in a time and dependent manner
(Cao et al., 2005, Cao et al., 2003). Taken together, PANDER induced LXR activation may
provide a central rationale for the observed pleiotropic actions of this novel hormone in both
the liver and pancreas.
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During preparation of this manuscript, the first report examining circulating PANDER is
currently in-press and measured these levels in an Asian population (n=212, aged 40–65)
with varying degrees of glucose intolerance and T2D (Cao, Yang, Lai et al., 2015). Cao et al.
revealed systemic PANDER levels are significantly correlated with increased fasting blood
glucose (FBG), triglycerides, and high-density lipoprotein cholesterol. Furthermore, logistic
regression analysis showed circulating PANDER was associated with increased risk of IGT
or T2D following cofounder adjustment. In general, they found that elevated plasma
PANDER was significantly associated with numerous metabolic syndrome components,
which is certainly consistent with our proteomic investigation and other animal model
studies revealing increased lipogenesis or hepatic steatosis during conditions of increased
PANDER expression. Further studies are needed and the almost near absence of human
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clinical and physiological in-vivo data presents a major limitation in the understanding of
PANDER and etiological role within T2D. However, our proteomic investigation certainly
supports the findings of this initial clinical study in that increased PANDER levels are
associated with both increased hepatic lipogenesis and it’s potential consequences in humans
such as promoting or initiating T2D or Metabolic Syndrome. Given that LXR is an
important gene in the regulation and homeostasis of cholesterol (Repa and Mangelsdorf,
2000), PANDER-induced effects on cholesterol may also be mediated by the LXR pathway.
LXR also regulates the transcription of CYP7A1, the rate limiting step of converting
cholesterol to bile acid as to effectively rid the cell of cholesterol (Chiang, Kimmel and
Stroup, 2001). LXR activation also promotes the generation of other lipogenic genes
increasing lipid accumulation and fatty acid synthesis. Accompanying this is the evidence of
increased triglycerides seen phenotypically in the PANTG mouse in previous studies
(Robert-Cooperman et al., 2014, Li et al., 2011). Additional studies are needed to precisely
address both the molecular mechanism of PANDER-induced lipogenesis and the potential
detrimental consequences when circulating levels are increased in humans in terms of the
role in both initiation and onset of T2D or hepatic steatosis.
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Highlights
•

Hepatic SILAC proteomics was performed on PANDER transgenic

•

3304 total unique hepatic proteins were identified

•

Cellular function altered in PANTG for all metabolic states was lipid
metabolism

•

Liver-X receptor activation predicted by proteomics and validated in-vivo and

in-vitro
•

Liver-X receptor activation may regulate the pleiotropic actions of PANDER
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Figure 1. SILAC proteomic experimental approach for investigation of PANTG
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A & B. Age and gender matched PANTG and WT mice at six weeks of age (N=3 per
condition) were exposed to three metabolic states prior to liver extraction: fed, fasted and
insulin-stimulated. Livers were immediately extracted following exposure to described
metabolic conditions, snap-frozen and stored at −80°C. C. & D. 40 mg of liver tissue were
lysed in cold lysis buffer (100mM Tris-HCl, 100mM DTT, 4% SDS and 1x HALT protease
inhibitor) prior to heating at 95°C for five minutes followed by brief sonication. Identical
process was performed on lives obtained from metabolically labeled “SILAC” mice
(Cambridge Isotopes). The “heavy” protein lysate was combined with each experimental
mouse liver protein lysate prior to tryptic digestion utilizing the FASP (Expedeon) method.
Samples were desalted using solid phase enrichment C18 columns (The Nest Group, Inc.).
Prior to LC-MS/MS, sample complexity was reduced by strong cation exchange
chromatography. E. & F. Each biological sample was analyzed by tandem mass
spectrometry. Normalized ratios from MaxQuant for each biological sample were inputted
into the Perseus processing suite to determine statistical significance of quantitation values
using a student’s two-tailed t test (p < 0.05) yielding 231 proteins in the fed condition, 246
proteins in the fasted condition and 191 proteins in the insulin-stimulated condition.
Geometric means and Uniprot Protein Identification numbers were uploaded to Ingenuity
Pathway Analysis (IPA) for canonical pathway and network analysis altered in the liver of
mice with increased circulating PANDER.
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Figure 2. IPA determination of altered molecular and cellular functions with the PANTG liver

Molecular and cellular function analysis was determined based on the identified
differentially expressed proteins of the PANTG and WT liver expression. Only functions that
were identified in all metabolic states of insulin-stimulated (Top Bar, White Fill), fed
(Middle Bar, Gray Fill) and fasting (Bottom Bar, Black Fill) conditions with a score cutoff
of −log(p-value) greater than two are shown as determined by Fisher’s Exact test.
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Figure 3. Network analysis of significantly differentially expressed lipogenic associated proteins
during insulin stimulatory conditions in PANTG liver
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Proteins with a positive association with increased lipogenic states of both fatty acid
metabolism and concentration of lipid are shown. Orange dotted lines indicate strong direct
association between shown proteins and the predicted activation of fatty acid metabolism
and concentration of lipid. The outer nodes represent differentially expressed proteins where
red and green represent up- and downregulation, respectively. Protein names are as follows,
CYP2C8- cytochrome P450, family 2, subfamily C, polypeptide 8, ACLY- ATP citrate lyase,
ACOT13- acyl-CoA thioesterase 13, C3- complement component 3, ENTPD5ectonucleoside triphosphate diphosphohydrolase 5, EPHX1- epoxide hydrolase 1, FABP1
fatty acid binding protein 1, FABP2- fatty acid binding protein 2, FASN- fatty acid synthase,
HMOX1- heme oxygenase 1, LSS- lanosterol synthase, SCD- stearoyl-CoA desaturase,
SEC16B- SEC16 homolog B, endoplasmic reticulum export factor, SLC9A3R1- solute
carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 regulator 1,
SORBS1- sorbin and SH3 domain containing 1, STEAP4- STEAP family member 4, and
THRSP- thyroid hormone responsive.
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Figure 4. Canonical pathway analysis of significantly differentially expressed proteins during all
metabolic conditions in PANTG liver

Canonical pathways with a score cutoff of −log(p-value) greater than 5 as determined by
Fisher’s Exact test and z-score greater than 2 are shown in metabolic states of insulinstimulated (Top Bar, White Fill), fed (Middle Bar, Gray Fill) and fasting (Bottom Bar, Black

Fill).
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Figure 5. Western blotting and validation of LXRα and LXR targets (FASN and CYP7A1) in
insulin-stimulated PANTG mice

(A) Liver lysate (40 μg) from age and gender matched PANTG mice during overnight
fasting and insulin-stimulated conditions (n=3). Immunoblotting was performed to measure
expression of LXRα, FASN, CYP7A1 and loading control of GAPDH. Lanes: 1–3 and 4–6
are WT and TG liver lysate, respectively. Densitometric analysis on (B) LXRα expression;
(C) FASN and (D) CYP7A1. * P < 0.05 (ImageJ) for both conditions.
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Figure 6. PANDER increased LXRE transcriptional activity in BNL-CL2 cells

Reporter gene analysis was performed on BNL-CL2 liver-derived cells transfected with
LXRE-luciferase plasmids exposed to increasing concentrations of purified secreted
PANDER (AstraZeneca) followed by measurement of luciferase activity. Treatments
performed in triplicate in duplicate biological experiments. *** denotes P < 0.001 as
determined by Students t-test from 0 nM PANDER condition.
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List of metabolic functions with significantly predicted increased activation state based on activation z-score
identified during insulin conditions within PANTG liver as compared to WT.
Metabolic Functions

Predicted Activation State

Activation z-score

Total Proteins

fatty acid synthesis

Increased

2.9

27

concentration of lipid

Increased

2.57

26

oxidation of lipid

Increased

2.58

14

concentration of fatty acid

Increased

2.42

13

conversion of lipid

Increased

2.77

9
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